AVITA Medical, Inc. (RCEL) Reports Cohealyx I Mean Graft Readiness at 13.6 Days

AVITA Medical reported final Cohealyx I study results, with a mean graft readiness time of 13.6 days, beating the 28-day goal. Six-month follow-up in 40 patients showed healing, improved scar scores, and no adverse events. The company noted no new product launch, only extended results from April.

Original reporting
Published Nov 16, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AVITA Medical, Inc. (RCEL) Reports Cohealyx I Mean Graft Readiness at 13.6 Days — source image
Decision brief

The 30-second read

$RCELBullishLow
01

Why it matters

The disclosed 13.6‑day graft readiness surpasses the 28‑day target, indicating strong early efficacy and safety, which could improve the company's valuation if later trials confirm these results.

02

Market read

First public release of Phase I data provides new, material information for investors; likely modest price impact pending further trial milestones.

03

What to watch

Regulatory pathway and reimbursement landscape remain uncertain, which could temper price gains.

Relevance 8/10Novelty 8/10Timing: today

Background

AVITA Medical (RCEL) is a biotech focused on advanced wound‑care products. The Cohealyx graft is a proprietary technology for treating full‑thickness wounds.

Company-level read

Ticker impact

$RCELBullishMedium confidence
Context

AVITA Medical disclosed Phase I Cohealyx trial results showing graft readiness in 13.6 days versus a 28‑day goal.

Expected impact

potential upward pressure as market prices in the favorable clinical outcome

Evidence & confidence

First disclosure of trial efficacy; however, no commercial or regulatory milestone announced yet.

Market effects

May boost outlook for wound‑care and regenerative‑medicine sector.

Limited to US biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech community.

Counterpoint

Data may be too early to translate into commercial value; investors could wait for later‑stage trials.

Key entities

  • AVITA Medical, Inc.

    Developer of the Cohealyx wound‑care platform.

Related articles

$RCELMed

Avita Medical Q3 Earnings Call Highlights

Avita Medical (RCEL) reported Q3 revenue of $600,000 for PermeaDerm, stable from Q2. Gross margin rose to 84%, and net loss narrowed to $6.2M. The company secured $10M in credit and alleviated going-concern doubts. RECELL revenue and manufacturing efficiencies drove improvements.

$RCELMed

AVITA Medical Reports Third Quarter Results

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., November 5, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic a

$RCELMedAI 8/10

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%

Avita Medical (NASDAQ:RCEL) reported Q2 net loss of $7.7M, nearly $3M better than Q1, with cash use down to $3.2M and cash of $11.1M at quarter end. The company raised its 2026 revenue outlook and said it is within Perceptive Advisors debt revenue covenants, including a $73M 2026 target. Q2 sales rose 18%.

$RCELMedAI 8/10

AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript

AVITA Medical (RCEL) reported Q2 2026 revenue of $21.7M, up 18% year over year and 13% sequentially. RECELL revenue was $18.5M, Cohealyx $1.7M, and PermeaDerm $0.6M. Gross margin was 81.9%. Net loss was $7.7M ($0.25/share). Full-year 2026 guidance is $86M to $89M; cash flow breakeven targeted for Q4 2026.